Efficacy and Safety Study of the Misoprostol Vaginal Priming Insert (MVPI) Prior to Hysteroscopy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Ferring Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00925938
First received: June 19, 2009
Last updated: January 20, 2014
Last verified: January 2014
  Purpose

A Phase II, multicenter, double-blind, randomized, placebo-controlled, dose-ranging, study to assess the efficacy and safety of the 100, 200, 400, 800, 1200 and 1600 mcg Misoprostol Vaginal Priming Insert (MVPI) for Women Requiring Cervical Priming prior to an in-office hysteroscopy procedure. Each subject will be randomized to receive one vaginal insert. The study drug will be administered vaginally by a member of the clinical research team (Part I) or insert herself (Part II) 18 - 24 hours prior to the scheduled hysteroscopy clinic visit. The internal os of the cervix will be measured at baseline, just prior to the hysteroscopy and at the follow up visit. The primary outcome measure is change in diameter of the internal cervical os from baseline (pre-treatment) to just prior to the hysteroscopy procedure (post-treatment). The hypothesis is that treatment with the MVPI will soften and dilate the cervix better than placebo.


Condition Intervention Phase
Cervical Priming
Drug: misoprostol
Drug: placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Assess the Efficacy and Safety of the Misoprostol Vaginal Priming Insert for Women Requiring Cervical Priming Prior to a Hysteroscopy

Resource links provided by NLM:


Further study details as provided by Ferring Pharmaceuticals:

Primary Outcome Measures:
  • Change in Diameter of the Internal Cervical os From Baseline (Pre-treatment) to Just Prior to the Hysteroscopy Procedure (Post-treatment). [ Time Frame: Baseline to 18-24 hours ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Percent of Women Requiring Further Dilatation in Order to Allow Uterine Access [ Time Frame: 18 - 24 hours ] [ Designated as safety issue: No ]
  • Total Procedure Time From Insertion of the First Hegar Dilator to Completion of the Hysteroscopy Procedure; [ Time Frame: 18 - 24 hours ] [ Designated as safety issue: No ]
  • Physician Assessment of Ease of Cervical Dilation; [ Time Frame: 18 - 24 hours ] [ Designated as safety issue: No ]
  • Percentage of Participants With Adverse Events [ Time Frame: 9 days ] [ Designated as safety issue: Yes ]

Enrollment: 51
Study Start Date: January 2010
Study Completion Date: November 2010
Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Misoprostol vaginal priming insert (MVPI)
One vaginal insert administered 18 - 24 hours prior to the scheduled hysteroscopy clinic visit. The initial dose is 400 mcg and dose will be adjusted between 100 - 1600 mcg after each study cohort based on safety and efficacy criteria as assessed by the Data and Safety Monitoring Board (DSMB).
Drug: misoprostol
One vaginal insert containing 100, 200, 400, 800, 1200, 1600 mcg misoprostol administered intravaginally one time and remain in place for 18 - 24 hours prior to the hysteroscopy procedure. An adaptive design will be used to determine whether to escalate or reduce the dose, starting with MVPI 400 mcg.
Placebo Comparator: MVPI Placebo
One vaginal insert of placebo administered 18 - 24 hours prior to the scheduled hysteroscopy clinic visit.
Drug: placebo
placebo

Detailed Description:

Prior to the hysteroscopy procedure, study staff will record the type of procedure that will be conducted and the desired cervical dilatation. The study drug will be removed in the office and then a vaginal examination will be performed for signs of irritation or trauma. The diameter of the internal os will then be assessed using Hegar dilators. The diameter of the internal os will be assessed by the largest size of Hegar dilator that can be inserted into the internal os without resistance. If the subject requires further dilatation prior to the procedure, this will be noted; additional dilatation is per clinician preference. The use of a tenaculum to allow insertion of the dilator(s)/ hysteroscope should be recorded. The time of starting and ending the hysteroscopy procedure will be documented. The start time of the hysteroscopy procedure is taken from the time of insertion of the first Hegar dilator to completion of the hysteroscopy procedure. Cervical priming assessment and safety will be recorded.

The subject will attend the clinic for follow-up assessments 7 days after the procedure.

Adverse events and concomitant medications will be recorded throughout the study.

The study will use an adaptive design, beginning with the MVPI 400 mcg and escalating or reducing the dose depending on results seen with a particular dose.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Healthy, pre-menopausal women;
  • Women aged 18 years and above;
  • Women who are undergoing an in-office procedure requiring uterine access along with a cervical dilatation of at least 5.5 mm;
  • Women participating in Part 1 of study: Women who have had at least one vaginal delivery of at least 24 weeks gestation;
  • Women with Pap smear results that do not require further evaluation for at least one year as assessed by the investigator. Note: 1) results must be from a Pap smear obtained within one year of screening; 2) if results are unavailable or not current, a Pap smear must be obtained and results reviewed prior to study inclusion; 3) if a Pap smear is to be performed at screening, subject must have a negative pregnancy test confirmed prior to the Pap smear collection;
  • Women of child bearing potential: 1) Must have a negative urine pregnancy test at screening and just prior to study drug insertion, if this takes place on a different day from the screening visit; 2) Agree to use a highly effective method of birth control (defined as a low failure rate of less than 1% per year) as follows: implants, injectables, combined oral contraceptives, sexual abstinence from the date of the subject's last menstruation until completion of the follow-up visit, vasectomised partner or barrier method (condom with spermicide). Women in a same sex relationship do not need to meet this criterion if they confirm that there is no possibility of pregnancy;
  • Women who agree to refrain from vaginal intercourse while the study drug is in place;
  • Women who agree to refrain from using any of the following from the day of study drug insertion until completion of the follow-up visit: feminine deodorant sprays/products, spermicides*, douches, condoms*, tampons, diaphragms or any other pharmaceutical or over the counter vaginal product. Barrier methods of contraception as indicated above (*) may be resumed following the dilatation procedure;
  • Women who provide written informed consent.

Exclusion Criteria:

  • Menopausal women;
  • Women with menstrual periods lasting >10 days in duration;
  • Baseline internal cervical os ≥ 3 mm;
  • Women who have had prior endometrial ablation;
  • Women who are breastfeeding;
  • History or current diagnosis of glaucoma;
  • Women with clinically significant vaginal or cervical abnormality (e.g. symptoms of an infection) that would interfere with conducting study procedures prior to study drug insertion;
  • Women who are currently undergoing treatment for cancer (basal cell carcinoma is acceptable);
  • Body Mass Index (BMI) ≥ 50;
  • Women participating in Part 1 of study: Women with a history of loop electrosurgical excision procedure (LEEP) or cold knife conization without an intervening vaginal delivery;
  • Women with an intra-uterine device (IUD) in place, had an IUD removed within 30 days of the screening visit or scheduled to have an IUD inserted during the hysteroscopy procedure;
  • Women using NuvaRing® for contraception;
  • Known or suspected allergy to misoprostol, other prostaglandins or any of the excipients;
  • Unable to comply with the protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00925938

Locations
United States, Arizona
Precision Trials
Phoenix, Arizona, United States, 85032
United States, North Carolina
Lyndhurst Gynecologic Associates
Winston-Salem, North Carolina, United States, 27103
Sponsors and Collaborators
Ferring Pharmaceuticals
Investigators
Study Director: Clinical Development Support Ferring Pharmaceuticals
  More Information

No publications provided

Responsible Party: Ferring Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00925938     History of Changes
Other Study ID Numbers: Miso-Gyn-201
Study First Received: June 19, 2009
Results First Received: October 23, 2013
Last Updated: January 20, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Ferring Pharmaceuticals:
Hysteroscopy
Cervical priming
Cervical dilatation
Misoprostol
Endoscopy, uterine

Additional relevant MeSH terms:
Misoprostol
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Pharmacologic Actions
Therapeutic Uses
Anti-Ulcer Agents
Gastrointestinal Agents
Oxytocics

ClinicalTrials.gov processed this record on September 18, 2014